Intradermal administration of DNA vaccines via a gene gun represents a feasible strategy to deliver DNA directly into the professional antigen-presenting cells (APCs) in the skin. This helps to facilitate the enhancement of DNA vaccine potency via strategies that modify the properties of APCs. We have previously demonstrated that DNA vaccines encoding human papillomavirus type 16 (HPV-16) E7 antigen linked to calreticulin (CRT) are capable of enhancing the E7-specific CD8 + T-cell immune responses and antitumor effects against E7-expressing tumors. It has also been shown that cluster (short-interval) DNA vaccination regimen generates potent immune responses in a minimal time frame. Thus, in the current study we hypothesize that the cluster intradermal CRT/E7 DNA vaccination will generate significant antigenspecific CD8 + T-cell infiltrates in E7-expressing tumors in tumor-bearing mice, leading to an increase in apoptotic tumor cell death. We found that cluster intradermal CRT/E7 DNA vaccination is capable of rapidly generating a significant number of E7-specific CD8 + T cells, resulting in significant therapeutic antitumor effects in vaccinated mice. We also observed that cluster intradermal CRT/E7 DNA vaccination in the presence of tumor generates significantly higher E7-specific CD8
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+ T-cell immune responses in the systemic circulation as well as in the tumors. In addition, this vaccination regimen also led to significantly lower levels of CD4 + Introduction DNA vaccines have emerged as an encouraging approach for antigen-specific immunotherapy due to their excellent safety profile, stability and ease of production. Intradermal administration of DNA vaccines via a gene gun serves as an efficient method to deliver DNA directly into the professional antigen-presenting cells in the skin, the dendritic cells (DCs). These DCs express the DNA and mature and migrate to the draining lymph nodes, where they activate naive T cells to differentiate into activated helper or killer T cells in vivo.
1,2 Thus, intradermal administration via a gene gun has enabled us to enhance DNA vaccine potency by using strategies to modify the properties of DCs (for review, see Hung et al. 3 and Tsen et al. ). One strategy to enhance DNA vaccine potency is to improve antigen expression, processing and presentation in DCs using intracellular targeting strategies (for review, see Hung et al. 3 and Tsen et al. 4 ). Several of our previous studies have employed DNA vaccines encoding human papillomavirus type 16 (HPV-16) E7 antigen linked to calreticulin (CRT) [5] [6] [7] [8] [9] [10] and have shown that these vaccines are capable of enhancing the E7-specific CD8 + T-cell immune responses in vaccinated mice. Furthermore, mice vaccinated with the DNA vaccines encoding CRT/E7 have been shown to generate stronger antitumor effects against E7-expressing tumors when compared with mice vaccinated with wild-type E7 DNA.
In general, current DNA vaccination strategies employ regimens of multiple intradermal or intramuscular administrations, with about 2 week intervals, and require at least 1 month to achieve immunity. 11, 12 This may be the cause for the relatively slow development of T-cell immune responses after DNA vaccination in contrast to the rapid immune responses induced by physiological antigen encounter, such as viral infection. It has been shown that a cluster (short-interval) DNA vaccination method generates potent humoral as well as T cell-mediated immune responses within a minimal time frame. 13 Thus, we aim to employ this novel cluster vaccination regimen in order to generate potent immune responses following DNA vaccination. In the current study, we hypothesized that the cluster intradermal CRT/E7 DNA vaccination would generate significant antigen-specific CD8 + T-cell infiltrates in E7-expressing tumors, TC-1, in tumor-bearing mice. Furthermore, we reasoned that effective vaccination would result in an increase in apoptotic tumor cell death. Thus, we have investigated the effect of cluster intradermal CRT/E7 DNA vaccination in TC-1 tumor-bearing mice. Our data serve as an important foundation for future clinical translation.
Results
Cluster intradermal CRT/E7 DNA vaccination rapidly induces E7-specific CD8 + T cells compared to long-interval DNA vaccination
In order to determine if cluster intradermal CRT/E7 DNA vaccination would rapidly induce E7-specific immune responses in vaccinated mice, we performed intracellular cytokine staining followed by flow cytometry analysis. C57BL/6 mice (five per group) were vaccinated twice with pNGVL4a-CRT/E7(detox) DNA vaccine at either 4 days interval (short interval/cluster vaccination) or 7 days interval (long interval). The vaccination regimen is depicted in Figure 1a . Splenocytes were harvested on days 8 and 14 after the initial vaccination and characterized for E7-specific CD8 + T cells using intracellular interferon (IFN)-g staining followed by flow cytometry. As shown in Figure 1b , the cluster intradermal DNA vaccination schedule generated robust E7-specific CD8 + T-cell immune responses as measured on days 8 and 14 (Po0.05). We also followed the immune responses for 3 weeks after the initial vaccination. We observed that the level of E7-specific CD8 + T-cell immune responses were quite comparable between cluster and long-interval DNA vaccination regimens (Supplementary Figure 1) . Thus, our data suggest that cluster intradermal DNA vaccination is capable of rapidly generating E7-specific CD8 + T-cell Figure 1 Characterization of E7-specific CD8 + T-cell immune responses in mice vaccinated with pNGVL4a-CRT/E7(detox) DNA vaccine. C57BL/6 mice (five per group) were vaccinated twice intradermally with pNGVL4a-CRT/E7(detox) DNA vaccine (2 mg per mouse) via gene gun at either 7 days interval (long interval) or 4 days interval (short interval/cluster vaccination). Cluster intradermal CRT/E7 DNA vaccination is capable of generating significant therapeutic antitumor effects against E7-expressing tumors
The ability of cluster DNA vaccination regimen to rapidly induce robust E7-specific T-cell immune responses in vaccinated mice raised the possibility that this regimen may lead to better therapeutic antitumor effects against E7-expressing tumors compared to DNA vaccination using the long-interval regimen. One explanation for such may be that the tumor load would be relatively less at the completion of cluster DNA vaccination. We therefore performed in vivo tumor treatment experiments using E7-expressing TC-1 tumors. C57BL/6 mice (five per group) were inoculated with TC-1 tumor cells subcutaneously. The TC-1 tumor-bearing mice were then treated with the pNGVL4a-CRT/E7(detox) DNA vaccine using either the cluster or long-interval vaccination regimen. The vaccination regimen is depicted in Figure 2a . As shown in Figure 2b , we found that the tumor-bearing mice treated with the pNGVL4a-CRT/ E7(detox) DNA vaccine using the short-interval cluster vaccination schedule demonstrated significantly better antitumor therapeutic effects, compared to the mice vaccinated using the long-interval vaccination schedule (Po0.05). Thus, our data suggest that cluster intradermal DNA vaccination is capable of generating potent therapeutic antitumor effects against E7-expressing tumors.
Cluster intradermal CRT/E7 DNA vaccination in the presence of tumor generates significantly higher E7-specific CD8 + T-cell immune response compared to vaccination after tumor resection
We further determined if the presence of tumor would influence the E7-specific CD8 + T-cell immune responses generated by cluster pNGVL4a-CRT/E7(detox) DNA vaccination. C57BL/6 mice (five per group) were inoculated subcutaneously with TC-1 tumor cells. After 10 days, these mice then received cluster intradermal vaccination with pNGVL4a-CRT/E7(detox) DNA vaccine (4aCRT/E7(detox)+TC-1). Another group of tumorbearing mice received tumor resection on day 10. After 2 days, these mice were vaccinated with the same dose and regimen (4aCRT/E7(detox)ÀTC-1). As shown in Figure  3a , we observed a significantly higher number of E7-specific CD8 + T cells in the mice vaccinated with pNGVL4a-CRT/E7(detox) DNA vaccine in the presence of tumor compared to those in mice vaccinated with the same dose and regimen after tumor resection (Po0.05). A graphical representation of the number of E7-specific CD8 + T cells is depicted in Figure 3b . We also characterized the E7-specific T cells in TC-1 tumorbearing mice without pNGVL4a-CRT/E7(detox) DNA vaccination. We found that only low levels of E7-specific T cells were detected in TC-1 tumor-bearing mice without the DNA vaccination compared to TC-1 tumorbearing mice treated with pNGVL4a-CRT/E7(detox) DNA vaccine (Supplementary Figure 2) . Thus, our data indicate that cluster intradermal CRT/E7(detox) DNA vaccination in the presence of tumor generates Cluster intradermal vaccination with CRT/E7(detox) in the presence of tumor generated significant E7-specific CD8 + T-cell immune response in tumor-infiltrating lymphocytes and in draining lymph nodes of vaccinated mice
In order to determine if cluster intradermal vaccination with CRT/E7(detox) in TC-1 tumor-bearing mice will lead to an increase in the number of E7-specific CD8 + T-cell immune responses in the tumor-infiltrating lymphocytes and in draining lymph nodes compared to TC-1 tumor-bearing mice vaccinated with CRT DNA, we performed intracellular cytokine staining followed by flow cytometry analysis. C57BL/6 mice (five per group) were inoculated subcutaneously with TC-1 tumor cells. Ten days after tumor inoculation, the mice were vaccinated either with pNGVL4a-CRT/E7(detox) or pNGVL4a-CRT DNA vaccine. We observed a significantly higher number of E7-specific CD8 + T cells in tumor-infiltrating lymphocytes ( Figure 4a ) as well as in the draining lymph nodes (Figure 4c ) of the TC-1 tumorbearing mice vaccinated with pNGVL4aCRT/E7(detox) DNA vaccine compared to those in TC-1 tumor-bearing mice vaccinated with control pNGVL4a-CRT DNA (P&lt;0.05). A graphical representation of the number of E7-specific CD8 + T cells in tumor-infiltrating lymphocytes as well as in the draining lymph nodes is depicted in Figures 4b and d respectively. Thus, our data indicate that cluster intradermal vaccination with pNGVL4a-CRT/E7(detox) in the presence of tumor generated significant E7-specific CD8 + T-cell immune response in tumor-infiltrating lymphocytes and in draining lymph nodes.
Cluster intradermal vaccination with CRT/E7(detox) in the presence of tumor generated significantly lower levels of CD4 + T-regulatory cells. 14, 15 It has been generally accepted that the high levels of expression of Foxp3 is the most distinctive marker for the T-regulatory lineage, particularly in the murine system (for review, see Belkaid 16 and Colombo and Piconese
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). Furthermore, myeloid suppressor cells have been shown Effect of cluster intradermal DNA vaccination S Peng et al Figure 4 Intracellular cytokine staining followed by flow cytometry analysis to characterize the E7-specific CD8 + cell precursors in the tumor and draining lymph nodes of tumor-bearing mice vaccinated with pNGVL4a-CRT/E7(detox) DNA vaccine. C57BL/6 mice (five per group) were inoculated subcutaneously with 1 Â 10 5 per mouse of TC-1 tumor cells. Ten days after tumor inoculation, mice were vaccinated either with pNGVL4a-CRT/E7(detox) DNA vaccine or pNGVL4a-CRT DNA intradermally via gene gun at a dose of 2 mg per mouse three times with 4-day intervals. Tumor-bearing mice without vaccination were used as a control. Lymphocytes were harvested 7 days after the last vaccination and characterized for E7-specific CD8 + T cells using intracellular interferon (IFN)-g staining followed by flow cytometry. 
20,21
Cluster intradermal vaccination with CRT/E7(detox) in the presence of tumor leads to significantly enhanced apoptotic tumor cell death in vaccinated mice
In order to determine the apoptotic tumor cell death induced by the cluster intradermal CRT/E7(detox) DNA vaccination, we performed a terminal nucleotidyl trans- Figure 7b . Thus, our data indicate that CRT/E7(detox) DNA vaccination leads to enhanced apoptotic tumor cell death that correlates with the enhanced E7-specific CD8 + T-cell immune response in vaccinated mice.
Discussion
In the current study, we have investigated the effect of cluster intradermal CRT/E7 DNA vaccination in E7-expressing TC-1 tumor-bearing mice. We found that cluster intradermal CRT/E7 DNA vaccination is capable of rapidly generating a significant number of E7-specific CD8 + T cells, resulting in significant therapeutic antitumor effects in vaccinated mice. We also observed that cluster intradermal CRT/E7 DNA vaccination in the presence of tumor generates significantly higher E7-specific CD8 + T-cell immune responses in the systemic circulation as well as in the tumors. In addition, this vaccination regimen also led to significantly lower levels of CD4 +
Foxp3
+ T-regulatory cells and myeloid suppressor cells in peripheral blood and in tumor-infiltrating lymphocytes and ultimately led to apoptotic tumor cell death. Thus, our data serve as an important foundation for future clinical translation. The success of the cluster vaccination strategy using intradermal administration via gene gun warrants the consideration of the cluster vaccination strategy in other DNA vaccination methods such as intramuscular administration of DNA vaccine with or without electroporation.
In the current study we observed that vaccination of TC-1 tumor-bearing mice treated with the pNGVL4a-CRT/E7(detox) DNA vaccine generated significantly higher numbers of IFN-g-secreting, E7-specific CD8 + T cells compared to tumor-free mice treated with the same DNA vaccine. Several reasons may account for the observed phenomenon. First, we recently observed that TC-1 tumor-bearing mice have higher frequencies of IFN-g-secreting, E7-specific CD8 + T cells compared to mice without TC-1 tumors (Supplementary Figure 3) . 
Effect of cluster intradermal DNA vaccination S Peng et al
Therefore, the higher frequency of the E7-specific CD8 + T cells in TC-1 tumor-bearing mice (compared to tumorfree mice) may contribute to the observed higher numbers of E7-specific CD8 + T-cell immune response following the pNGVL4a-CRT/E7(detox) DNA vaccination. Second, in the current study, we observed that TC-1 tumor-bearing mice treated with the pNGVL4a-CRT/ E7(detox) DNA vaccine generated significantly higher numbers of tumor-apoptotic cell death compared to TC-1 tumor-bearing mice without the DNA treatment ( Figure  7) . We have recently observed that increased apoptotic tumor cell death of E7-expressing TC-1 tumors could result in increased frequency of E7-specific CD8 + T cells. 22 Thus, the potential increase in apoptotic cell death of E7-expressing TC-1 tumors following the initial DNA vaccine treatment may further contribute to the observed higher numbers of E7-specific CD8 + T-cell immune response following the repeated pNGVL4a-CRT/E7(detox) DNA vaccination. These factors may contribute to the mechanism by which the vaccine induces higher number of T cells in the presence of E7-expressing tumor.
We also observed significant reduction in the numbers of CD4 + Foxp3 + Treg cells and myeloid suppressor cells in peripheral blood as well as in tumor-infiltrating lymphocytes in mice vaccinated with the pNGVL4a-CRT/ E7(detox) DNA vaccine (Figures 5 and 6 + Treg and myeloid suppressor cells. For clinical translation of the therapeutic HPV DNA vaccines, it is important to consider issues relating to safety. Concerns are raised regarding the potential for oncogenicity associated with administration of E7 as DNA vaccines into the body. Thus, it is important to use attenuated (detox) versions of E7 that has been mutated. It has been demonstrated that a mutation at E7 positions 24 and/or 26 will disrupt the Rb-binding site of E7, abolishing the capacity of E7 to transform cells. 23, 24 In addition, clinical translation may preclude the use of the pcDNA3 vector, because it contains an ampicillinresistance gene. It will be important to use an appropriate DNA vector such as the pNGVL4a vector, which was obtained from the NIH National Gene Vector Laboratory for DNA vaccine development. This vector is a second-generation plasmid derived from pNGVL-3, which has been previously used for human clinical trials. 25 The pNGVL4a vector lacks the ampicillinresistance gene and thus would be suitable for clinical translation of the current DNA vaccines.
In fact, a phase I clinical trial is currently being planned using the cluster intradermal DNA vaccination regimen in stage IB1 cervical cancer patients (R Alvarez and C Trimble, personal communication). In this trial, we Effect of cluster intradermal DNA vaccination S Peng et al aim to investigate whether the cluster intradermal CRT/ E7 DNA vaccination is safe and able to generate E7-specific CD8
+ T-cell immune responses in patients with stage 1B1 cervical cancer. We have chosen stage IB1 patients because the standard care of stage IB1 cervical cancer patients allows us to resect the tumor and its draining lymph nodes, thus permitting us to evaluate the tumor microenvironment. The clustered vaccination regimen allows us to complete the vaccinations before tumor resection, thus making it possible to assess the changes in tumor microenvironment with or without DNA vaccination without compromising the standard care of the patient. The pNGVL4a-CRT/E7(detox) DNA vaccine has been formulated in a proprietary ND-10 gene gun device, which has been approved for clinical trials.
In summary, the current cluster intradermal DNA vaccine regimen is highly effective in inducing a rapid and potent E7-specific CD8 + T-cell immune response, resulting in antitumor effects and apoptotic cell death in E7-expressing tumors. Thus, the current study has immense potential for clinical translation in the near future.
Materials and methods
Mice, cell lines, peptides and antibodies C57BL/6 mice (6-to 8-week old) were purchased from the National Cancer Institute (Frederick, MD, USA). All animals were maintained under specific pathogen-free conditions, and all procedures were performed according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
E7-expressing TC-1 cells were generated as previously described 26 and were maintained in RPMI medium supplemented with 2 mM glutamine, 1 mM sodium pyruvate and 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), 5 Â 10 À5 M b-mercaptoethanol, 100 IU ml À1 penicillin, 100 mg ml À1 streptomycin and 10% fetal bovine serum.
The H-2D b -restricted HPV-16 E7 peptide, RAHY-NIVTF (E7 aa49-57), 27 was synthesized by Macromolecular Resources (Denver, CO, USA) at a purity of X70%. Antibodies against mouse CD4 (fluorescein isothiocyanate (FITC)-conjugated, clone RM4-5), Foxp3 (phycoerythrin (PE)-conjugated, FJK-16s) were purchased from eBiosciences (San Diego, CA, USA), CD11b (FITCconjugated, clone M1/70), Ly6-G (Gr-1, FITC or APCconjugated, clone RB6-8C5). Antibodies against mouse CD8 (PE-conjugated, clone 53.6.7), IFN-g (FITC-conjugated, clone XMG1.2), CD124 (PE-conjugated, clone mIL4R-M1) were purchased from BD Pharmingen (San Diego, CA, USA).
In vivo tumor treatment experiments
For in vivo tumor treatment experiments, C57BL/6 mice (five per group) were inoculated subcutaneously with 1 Â l0 5 TC-1 tumor cells per mouse on the left flank. Mice were monitored for tumor growth by measuring diameters with calipers twice a week.
Surgical resection of TC-1 tumors
TC-1 tumors were surgically excised on day 10 after tumor inoculation when the tumor size reached approximately 5-6 mm in diameter. Mice were anesthetized with isoflurane and tumors were excised and incisions were closed with 4-0 nylon. Mice with recurrent primary tumors after surgery (o10%) were excluded from the study.
DNA vaccination
Generation of pNGVL4a-CRT and pNGVL4a-CRT/ E7(detox) has been described previously.
10 E7(detox) represents an E7 gene with mutations at E7 positions 24 and 26, which disrupt the Rb-binding site of E7. The mutation at these locations abolishes the capacity of E7 to transform cells. 23, 24 Clinical grade pNGVL4a-CRT/ E7(detox) plasmids were prepared by NIH Rapid Access to Interventional Development (RAID). For the gene gun-mediated intradermal vaccination, DNA-coated gold particles (1 mg DNA per bullet, two bullets per vaccination) were delivered to the shaved abdominal region of C57BL/6 mice using a helium-driven gene gun device from Bio-Rad (Hercules, CA, USA), or ND-10 gene gun device from PowderMed/Pfizer with a discharge pressure of 400 p.s.i., according to a previously described protocol.
28 Naive C57BL/6 mice or TC-1 tumor-bearing mice (d10 after tumor inoculation) or TC-1 tumor postsurgical mice (2 days after resection) were vaccinated twice with 2 mg per mouse of pNGVL4a-CRT/E7(detox) DNA vaccine at either 4 days interval (short interval/cluster vaccination) or 7 days interval (long interval) as depicted in Figure 1a .
Preparation of single-cell suspensions from TC-1 tumors
One week after last vaccination, TC-1 tumors were surgically excised under sterile conditions and placed in RPMI 1640 medium containing 100 U ml À1 penicillin, 100 mg ml À1 streptomycin on ice, and washed with phosphate-buffered saline (PBS). A fraction of the tumors were either snap frozen in Tissue-Tek optimum cutting temperature (OCT) compound immediately (Sakura Finetek, Torrence, CA, USA) or fixed with 10% formalin. The remaining solid tumors were then minced into 1-to 2-mm pieces and immersed in serum-free RPMI 1640 medium containing 1 mg ml À1 collagenase D, and 0.25 mg ml À1 DNase I (both are from Roche, Indianapolis, IN, USA), 100 U ml À1 penicillin, 100 mg ml À1 streptomycin and incubated at room temperature overnight with gentle agitation. It was then filtered through a 70-mm nylon filter mesh to remove undigested tissue fragments. The resultant single tumor cell suspensions and tumor-infiltrating lymphocytes were washed twice in Hank's buffered salt solution (HBSS) (400 g for 10 min), and viable cells were determined using Trypan blue dye exclusion. For intracellular IFN-g staining, 5 Â 10 6 pooled splenocytes from each vaccination group were incubated with 1 m ml À1 of the HPV-16 E7 aa49-57 peptide in the presence of GolgiPlug (BD Pharmingen) at 37 1C overnight. Cells were then washed once with FACS wash buffer and stained with PE-conjugated monoclonal rat antimouse CD8a. Cells were subjected to intracellular cytokine staining using the Cytofix/Cytoperm kit according to the manufacturer's instruction (BD Pharmingen). Intracellular IFN-g was stained with FITC-conjugated rat antimouse IFN-g. Flow cytometry analysis was performed using FACSCalibur with CELLQuest software (BD Biosciences, Mountain View, CA, USA).
Intracellular cytokine staining and flow cytometry analysis

Apoptotic assays
TUNEL assay was carried out on paraffin-embedded tumor tissues using In Situ Cell Death Detection Kit, POD (Roche, Indianapolis, IN, USA). Tissue sectioning was performed by the Reference Histology Laboratory of Johns Hopkins University. The assay was carried out according to the manufacturer's instruction. Briefly, tissue sections were deparaffinized, permeabilized with the proteinase K (Roche) at 37 1C for 15 min, then the slides were incubated in 3% hydrogen peroxide in PBS at room temperature for 10 min. The sections were sequentially incubated in the labeling mixture contained terminal nucleotidyl transferase (TdT) and digoxigeninlabeled dUTP for 60 min at 37 1C. Then, the converter-POD (a peroxidase-conjugated antidigoxigenin antibody) was added to the tissue sections and the product was visualized by staining with the substrate DAB (3,3 0 -diaminobenzidine tetrahydrochloride) (Sigma, St Louis, MO, USA), followed by counterstaining with Hematoxylin (Dako, Carpinteria, CA, USA). Tissue sections processed without TdT enzyme were used as the negative control. Only nuclear staining was considered as positive. The data were generated using 200 Â HPF from 10 different fields for each tumor. Three tumors were used for each group.
Statistical analysis
All numerical data are expressed as mean±s.d. Comparisons between experimental and control groups were made using Student's t-test. All P-values less than 0.05 were considered statistically significant.
